Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3225402 | 1.00 | PPM1D (0.36) | PPM1DTSHR | |
| SCHEMBL1896226 | 0.96 | PPM1D (0.35) | PPM1DTSHR | |
| SCHEMBL6399612 | 0.96 | TSHR (0.40) | PPM1DTSHR | |
| SCHEMBL29789152 | 0.89 | PPM1D (0.38) | PPM1D | |
| SCHEMBL9985676 | 0.89 | PPM1D (0.38) | PPM1D | |
| SCHEMBL5711230 | 0.89 | PPM1D (0.38) | PPM1D | |
| SCHEMBL5711228 | 0.89 | PPM1D (0.38) | PPM1D | |
| SCHEMBL660447 | 0.89 | PPM1D (0.38) | PPM1D | |
| SCHEMBL277967 | 0.88 | PPM1D (0.33) | PPM1D | |
| SCHEMBL278515 | 0.88 | PPM1D (0.33) | PPM1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2125745-B1 | CYCLOALKYLAMINE SUBSTITUTED ISOQUINOLONE DERIVATIVES | SANOFI SA (FR) | 2017-02-22 | — | — | EP | disclosed |
| US-8742116-B2 | Cycloalkylamine substituted isoquinolone derivatives | SANOFI (FR) | 2014-06-03 | — | — | US | disclosed |
| EP-2007719-B1 | INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | ABBOTT LAB (US) | 2012-05-02 | — | — | EP | disclosed |
| EP-2407452-A1 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme | Abbott Laboratories (US) | 2012-01-18 | — | — | EP | disclosed |
| US-7737137-B2 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme | ABBOTT LABORATORIES (US) | 2010-06-15 | — | — | US | disclosed |
| US-20100056518-A1 | CYCLOALKYLAMINE SUBSTITUTED ISOQUINOLONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2010-03-04 | — | — | US | disclosed |
| EP-2007719-A2 | INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | Abbott Laboratories (US) | 2008-12-31 | — | — | EP | disclosed |
| US-20080312214-A1 | Inhibitors of the 11-Beta-Hydroxysteroid Dehydrogenase Type 1 Enzyme | ABBOTT LABORATORIES (US) | 2008-12-18 | — | — | US | disclosed |
| US-7435833-B2 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme | ABBOTT LABORATORIES (US) | 2008-10-14 | — | — | US | disclosed |
| US-20080076819-A1 | INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | ABBOTT LABORATORIES (US) | 2008-03-27 | — | — | US | disclosed |
| WO-2007118185-A2 | INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | ABBOTT LABORATORIES (US) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076819-A1 | INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | HSD11B1, HSD11B2, HSD17B1 | PPM1D 532/4885TSHR 2869/4885 |
| US-20080312214-A1 | Inhibitors of the 11-Beta-Hydroxysteroid Dehydrogenase Type 1 Enzyme | HSD11B1, HSD17B1, HSD11B2 | PPM1D 656/4885TSHR 1776/4885 |
| US-20100056518-A1 | CYCLOALKYLAMINE SUBSTITUTED ISOQUINOLONE DERIVATIVES | MYLK, MYLK2, MYLK3 | PPM1D 316/4885TSHR 4583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.